
|Videos|July 21, 2023
Key Retreatment Decisions in the Clinical Trials for Faricimab in nAMD
Author(s)Varun Chaudhary, MD, FRCS(C)
Dr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.
Advertisement
Episodes in this series
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Ophthalmic care uncommon after tamoxifen initiation
2
Global Summit for Eye Health 2026: Turning pledges into eye care
3
Distinguishing Lambert-Eaton myasthenic syndrome from ocular myasthenia gravis in the eye clinic
4
Empire Forum 2026: Ambati on K8 phase 2 results in geographic atrophy
5













